Powder formation by atmospheric spray-freeze drying

Information

  • Patent Grant
  • 8322046
  • Patent Number
    8,322,046
  • Date Filed
    Tuesday, March 18, 2008
    16 years ago
  • Date Issued
    Tuesday, December 4, 2012
    12 years ago
Abstract
A method of manufacturing heat-sensitive pharmaceutical powder is disclosed. The original pharmaceutical substances are dissolved in a solution or suspended in a suspension, which is sprayed through an atomizing nozzle and frozen in a cold gas phase or liquid nitrogen atomized directly in the spray-freeze chamber or gas jacket at the same time (for cooling purposes). The particles are freeze-dried at roughly atmospheric pressure in a down-stream fluid flow with exit filter thereby to remove moisture entrapped on or inside the frozen particles. The system has applicability for forming other powders.
Description
BACKGROUND OF THE INVENTION

This invention relates to the preparation of powders, particularly for the administration of pharmaceuticals to humans.


Pharmaceuticals are often unstable compounds that degrade rapidly during processes that lead to a powder form of the pharmaceutical. Since the pharmaceutical compound is usually carried in an aqueous solution, and the aqueous solution must be dried to form the powder, the required desiccation or drying process may easily damage the pharmaceutical. At the same time, if the process of forming the powder takes too long, or is too energy consuming, the process may become uneconomic.


Freeze drying (lyophilization), which has conventionally been used to prepare pharmaceutical powders, provides a two step preservation and dehydration process in which the product is first frozen and the water is then removed as vapor from the frozen state. As the water passes from the solid phase directly into the vapor phase, it is necessary that the vapor pressure and the temperature of the sublimation zone is held below those of the triple point on the phase diagram for water. The temperature (<<0° C.) and the maintenance of the frozen state lead to very low driving forces for heat and mass transfer and therefore, often to very low drying rates and very long drying times. Thus, despite its capability of providing a very high-quality dehydrated product, freeze-drying has been and remains highly energy-intensive and consequently, is a very expensive dehydration process.


Freeze drying conventionally is carried out in a vacuum, but may also be carried out at or near atmospheric pressure. Atmospheric freeze-drying has been shown to have the added advantage of increasing transfer coefficients and improving the uniformity of the product during lyophilization. For example, Meryman, H. T., Sublimation freeze-drying without vacuum. Science, 130 (1959) 628-629 proposed an atmospheric freeze-drying process in which the partial pressure of water in the drying chamber is held at very low value and he suggested that such a process should be based on the principle of convective freeze drying, i.e. a cold air steam, kept dry by a molecular sieve desiccant or by a refrigerated condenser, should be circulated. More recently, Leuenberger, H., Spray freeze-drying—the process of choice for low water soluble drugs, Journal of Nanoparticle Research, 4:111-119, 2002 has also identified that spray freeze drying helps preserve pharmacological activity of drugs by stabilization in an appropriate matrix.


Despite the potential advantages of atmospheric lyophilization, the challenge still remains to provide a combination of spray-freezing solution/suspension into liquid and atmospheric freeze-drying that meets industrial demands for a pharmaceutical powder process that maintains drug bioactivity at low economic cost.


SUMMARY OF THE INVENTION

It is therefore an object of this invention to provide atmospheric spray freeze drying of liquid carrying pharmaceuticals to produce a powder by a pharmaceutical powder process that maintains drug bioactivity at low economic cost. The invention provides a method of manufacturing a powder or particulate pharmaceutical substance, and an apparatus for carrying out the method. The powder produced by this process is believed to exhibit higher emitted dose and better preservation of bioactivity than spray-dried particles and milled particles. In addition, the porous nature of the particles provides rapid dissolution properties. The invention is applicable to the formation of other powders, including powder forms of nutraceuticals and foods.


Therefore, according to an aspect of the invention, there is provided a method of creating a powder, comprising spraying a carrier liquid containing a powder forming ingredient to form a flow of liquid droplets; entraining the flow with a coolant for sufficient time to freeze the liquid droplets into frozen particles; and drying the frozen particles to form a dry powder.


According to a further aspect of the invention, there is provided apparatus for atmospheric spray freeze drying of an ingredient carrying liquid to form a powder, the apparatus comprising: a chamber having an atomizer at one end of the chamber, the atomizer being connected to a source of the ingredient carrier liquid to produce a flow of liquid droplets; a nozzle system for providing a flow of coolant that entrains atomized fluid sprayed by the atomizer; a source of coolant for the nozzle system; and a collector spaced from the atomizer sufficiently that liquid droplets atomized by the atomizer are frozen by the flow of coolant before contact with the collector.


The powder forming ingredient may be suspended or dissolved in the carrier liquid. The entraining flow may be a concurrent flow of coolant, for example as sprayed from a ring nozzle or through porous side walls of a confining chamber. Frozen particles are preferably collected on a filter at an exit from the confining chamber, and drying mostly takes place on the filter. For enhanced drying, the flow over the filter should be at a warmer temperature than for freezing. More than one powder forming ingredient may be present in the carrier liquid.


Other aspects of the invention appear in the claims.





BRIEF DESCRIPTION OF THE DRAWINGS

There will now be described preferred embodiments of the invention with reference to the figures, by way of example, and without intending to limit the scope of the invention to the precise examples disclosed here, and in which figures:



FIG. 1 shows a first embodiment of a device for accomplishing atmospheric spray freeze drying according to the invention;



FIG. 2 shows a second embodiment of a device for accomplishing atmospheric spray freeze drying according to the invention; and



FIG. 3 shows a third embodiment of a device for accomplishing atmospheric spray freeze drying according to the invention.





DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS OF THE INVENTION

The word “comprising” in the claims is used in its inclusive sense and does not exclude other elements being present. The use of the indefinite article “a” in a claim before an element does not exclude more than one of the element being present.


The present invention is widely applicable for producing particulate material and can be used for spray-freeze drying any material amenable to dissolution or suspension in a suitable carrier liquid, such as water. The term powder forming ingredient is used to refer to one or more pharmaceutical, nutraceutical, food or other substances that have utility in powder form. The present invention is especially useful for heat-sensitive substances, such as proteins, nucleic acids, oligonucleotides, enzymes, liposomes, lipids, lipid complexes, anti-virals and vaccines (e.g. involving nonvirulent or attenuated pathogens), carbohydrates, polymers, polysaccharides, and peptides. However, its use is not limited to only large molecules, since the method always produces a powder from any material dissolved or suitably suspended in water; it may be used to create, for example, powder anti-infectives, anti-microbials, anti-inflammatories, antineoplastics, analgesics, anaesthetics, cholinergics, adrenergics, anticonvulsants, anti-depressants, sedatives, tranquilizers and antiemetics, immunosuppressives and immunostimulants, antihistamines, hormones, antivenoms and antitoxins. Cryoprotectants may be added to aid in preventing degradation of substances during processing. The ingredient carrying liquid may contain several different drugs and also excipient material. For example, the particles may be made mostly out of lactose with only a little drug in them. Or there may be several drugs in the ingredient carrying liquid, plus lactose or other filler/matrix/excipient compound.


In the embodiments shown in FIGS. 1, 2 and 3, a flow or spray of atomized carrier fluid is frozen into a powder of solid particles by an entraining flow of coolant and subsequently dried by providing a flow of desiccating gas over the powder. Entraining by the cooling gas provides for confining the spray, and immediate freezing of the individual spray droplets, so that the liquid spray droplets do not impact on the walls of the chamber in which the process is carried out.


Referring to the first embodiment shown in FIG. 1, a housing 100 formed with solid insulated walls supports at an inlet end an atomizer 102 that is supplied through line 104 with compressed gas from source 106 and a suitable carrier liquid from source 108. Inside the housing 100 is a flow chamber 110 with porous walls. The flow chamber 110 is formed of cylindrical sections 112, 114 of differing diameter joined by a conical section 116. Multiple nozzles 118 of a nozzle system penetrate the housing 100 and supply a cryogenic flow of coolant from a coolant source 120 into the space between the housing 100 and flow chamber 110. At the other, exit, end of the housing 100 from the atomizer 102, the flow chamber 110 terminates in a filter 122 that is held across an opening in the housing 100 by a plate 124 fixed to the chamber 100 by bolts or clamps 126 with O-ring 128. Gas flow from the exit end of the housing 100 is returned to a refrigerated condenser that forms part of the coolant source 120. The refrigerated condenser strips moisture from the cooling gas for re-use of the cooling gas.


Referring to a second embodiment shown in FIG. 2, a housing 200 formed with solid insulated walls supports at an inlet end an atomizer 202 that is supplied through line 204 with compressed gas from source 206 and a suitable carrier liquid from source 208. Inside the housing 200 is a flow chamber 210 defined by solid walls lining the housing 200. The flow chamber 210 is formed of cylindrical sections 212, 214 of differing diameter joined by a conical section 216. Surrounding the atomizer 202 is a nozzle system in the form of a ring nozzle 218, with openings 219 directing flow from the ring nozzle 218 parallel to flow from the atomizer 202. The ring nozzle 218 supplies a cryogenic flow of coolant from a coolant source 220, for example a liquid nitrogen cylinder driven by compressed gas that surrounds flow from the atomizer 202 in the spray-freezing step and a refrigerated condenser in the following drying step. At the other, exit, end of the housing 200 from the atomizer 202, the flow chamber 210 terminates in a filter 222 that is held across an opening in the housing 200 by a plate 224 fixed to flanges 225 on the chamber 200 by bolts or clamps 226 with O-ring 228.


Referring to a third embodiment shown in FIG. 3, a housing 300 formed with solid insulated walls supports at an inlet end an atomizer 302 that is supplied through line 304 with compressed gas from source 306 and a suitable carrier liquid from source 308. Inside the housing 300 is a cylindrical flow chamber 310 defined by solid walls lining the housing 300. Surrounding the atomizer 302 is a ring nozzle 318, with openings 319 directing flow from the ring nozzle 318 parallel to flow from the atomizer 302. The ring nozzle 318 supplies a cryogenic flow of coolant from a coolant source 320, for example a liquid nitrogen cylinder driven by compressed gas that surrounds flow from the atomizer 302 in the spray-freezing step and a refrigerated condenser in the following drying step. At the other, exit, end of the housing 300 from the atomizer 302, the flow chamber 310 terminates in a filter 322 that is held across an opening in the housing 300 by a plate 324 fixed to flanges 325 on the chamber 300 by bolts or clamps 326 with O-ring 328.


The coolant source 120, 220 or 320 may be any source of a coolant that does not contaminate or degrade the powder. Cold gas may be used such as refrigerated nitrogen, particularly for the embodiment shown in FIG. 1. The nitrogen may also be obtained from a liquid nitrogen cylinder driven by compressed gas, particularly for the embodiment shown in FIGS. 2 and 3. Upon exiting the nozzles 118, 218 and 318, cold gas or liquid, for example cold liquid nitrogen or cold gaseous nitrogen, which may be sourced from a cylinder of liquid nitrogen or other cryogenic source of nitrogen, will entrain the spray and freeze the liquid drops of the spray. For freezing followed by drying, both a liquid nitrogen source and a refrigeration unit may be used. Freezing may be carried out using the liquid nitrogen source, as in the embodiment of FIGS. 2 and 3, and then drying may be carried out at warmer temperatures using the refrigeration unit.


During manufacture, pharmaceutical agents (PA) or other powder forming ingredients are mixed with a carrier liquid prior to spraying from the atomizer 102, 202, 302. The spray fluid resulting from the mixture of PA and carrier liquid may be, for example, a solution, a suspension or a colloid. The atomizer 102, 202, 302 may be a two-fluid nozzle or an ultrasonic nebulizer or a vibrating orifice aerosol generator (VOAG) or other atomizing device. The spray fluid, which is formed of liquid droplets, is rapidly frozen through contact with coolant, which is a cold fluid of a suitable temperature. In the spray-freeze step, cooling fluid may be supplied in several possible ways. One way, shown in FIGS. 2, 3, is to spray cooling liquid such as liquid nitrogen directly into the chamber 200,300 by using the ring nozzle 218, 318, while spray droplets from atomizer 202, 302 inside the perimeter of the ring nozzle 218, 318 are frozen immediately after contacting the surrounding curtain of liquid nitrogen and then conveyed to the exit filter 222, 322 at the exit end of the housing 200, 300. Another way, shown in FIG. 1, is to have a cooling gas enter through porous walls 112, 114, 116 that enclose the atomizer 102. Gas supplied into the space between the housing 100 and chamber 110 forms a gas jacket whose temperature is adjusted by mixing with liquid nitrogen or an equivalent cryogenic at different ratios.


In the example of FIGS. 2 and 3, the curtain of spraying liquid nitrogen is used for freezing the spraying liquid droplets and avoiding cohesion of frozen powder on the sidewalls 210, 310. The spraying velocity and quantity of liquid nitrogen is controlled to meet both the cooling demand of the spray-freeze process and conveying of frozen powders to the exit filter 222, 322. In the example of FIG. 1, the flow passing through the porous sidewalls of the freezing chamber 110 has the same function as the spraying curtain of liquid nitrogen, i.e. reducing the particle cohesion and allowing a distinguishingly radial flow of cooling fluid into the chamber 110 to freeze liquid droplets and protect the liquid droplet/frozen particles from contacting the wall surface. The thickness of the porous sidewall 110 and pressure inside the gas jacket, which is controlled by the flow rate of cooling gas into the chamber 100, are adjusted for the particular powder being processed. Thereafter, a down-flow transport by virtue of the spray direction of the atomizer 102 is automatically formed in the spray-freeze process to carry all the frozen powder to the exit end of the chamber 100.


After the accomplishment of spray-freezing, a proper drying temperature will be chosen in a drying step by flow rate adjustment from the cooling cryogenic or refrigeration system. In the meantime, the initial frozen powder collected on the exit filter 122, 222, 322 at exit end (bottom) of the chamber will be dried by sublimation in a cold desiccated airstream at atmospheric pressure. Because all the frozen powder falls down or is conveyed by the down stream flow to the exit filter, no matter whether it is cohesive powder or free flow powder, no external forces are needed to re-lift the powder adhering on the walls, unlike in the spray-freeze drying process of a traditional up-stream fluidized bed, which are used in other processes like U.S. Pat. No. 4,608,764.


In addition, less contamination is realized through this invention by screening frozen powder from contacting the sidewalls of the chamber 110, 210, 310 compared to the former technology. As the sublimation process is taking place, the frozen particles become lighter and the aerodynamic behavior changes. The partially dried particles may form a loose cake on the exit filter 122, 222, 322, from which the remaining moisture is removed by atmospheric sublimation using a cold desiccated gas stream, resulting in final free-flowing powders. After spray-freeze atmospheric drying, dry porous particles of roughly the same size and shape as the original frozen droplets are obtained.


Spray freeze atmospheric dried particles produced by this method can have a morphology desirable for respiratory administration of medicament using respiratory delivery devices such as those disclosed in U.S. patent application US60430085 filed Nov. 27, 2003. The typically porous nature of particles formed from this process is also desirable for rapid dissolution, as seen in the BioAqueous technology from Dow Chemical Company, as well as for other purposes such as those disclosed in e.g. U.S. Pat. No. 6,635,283.


Operating Procedures


The apparatus is allowed to run for approximately 5 to 30 minutes to reach the desired temperature in the chamber 110, 210, 310 either by spraying liquid nitrogen directly into it, or by having the cold fluid from a refrigeration system flow into the chamber 110 through the porous wall. The aqueous solution or suspension of the substances to be dried is then sprayed using the atomizer 102, 202, 302 and frozen simultaneously in situ at a chosen temperature by the surrounding curtain of liquid nitrogen generated from ring nozzle 218, 318 or an equivalent such as cryogenic flow from nozzles 118 through porous sidewalls of chamber 110. The frozen powder is conveyed down to the exit filter 122, 222, 322 by the concurrent downstream flow. After completion of the spray-freezing process, the flow of the cryogenic fluid (at a low temperature of −50° C. to −196° C.) is shut off and switched to a cooling gas at a somewhat higher temperature (−10° C. to −30° C.) from the refrigeration system. Then the frozen powder collected on the exit filter 122, 222, 322, at the bottom is dried continuously by sublimation at atmospheric pressure until the remaining moisture of the frozen powder is removed by the cold desiccated gas stream. After spray-freeze atmospheric drying, a loose cake occurs on the exit filter 122, 222, 322, which is very fragile and easily broken into free flowing, dry porous particles of approximately the same size and shape as the original frozen droplets. In order to reduce moisture condensation on the cold particle surface, the temperature of the desiccant cooling gas will be raised to room temperature gradually before the sample is collected from the chamber 100, 200, 300.


In one example, powder was produced using the method described above. A 15 wt % mannitol solution was spray freeze-dried using the apparatus shown in FIG. 1. A 15% mannitol (Mannitol USP powder, Fisher Scientific) aqueous solution was used to demonstrate the process. Before spraying, the chamber 110 for spray-freeze drying was allowed to run for approximately 20 minutes to reach the desired temperature (−65° C.). During the 20 minutes, the cold fluid from a refrigeration unit incorporating two parallel dry-ice cooling columns flows into the chamber 110 through the porous sidewall. A Chem-Tech pump (Model CTPA4LSA-PAP1-XXXX, Viking pump of Canada Inc, Windsor, Ontario, Canada) was used to pump 20 ml of 15% mannitol solution into an air atomizing spray nozzle 102 (Spraying Systems Co., Wheaton, Ill., USA) spraying into the chamber from the top with the aid of a compressed driving gas (nitrogen) at a flowrate of 0.6 SCFM. The spray-freezing process was finished within 4 minutes and meanwhile, the temperature in the chamber 110 was kept at −50° C. to −70° C. by the mixed cooling gas (nitrogen). In this case, the pressure in the chamber was almost atmospheric (around 1.02 atm). After the completion of spray-freeze process, the pump and driving gas for spraying was shut down and the cooling gas for drying was kept flowing at a flowrate of 60 L/min. The temperature in the chamber was kept at around −15° C. (−5° C. to −20° C.) by adjusting the height of dry ice in the cooling columns. After drying for 1 hr, the temperature in the chamber was raised to room temperature gradually within another 30 minutes at a flowrate of 30 L/min. Thereafter, the cooling gas was shut off and a dry powder cake on the exit filter 122 was collected. This cake was easily broken into a free-flowing powder and the resulting particles were found very porous and roughly spherical. The moisture content was measured to be only 0.9%. Photos from a scanning electron microscope (SEM) of one resulting sample powder collected from the exit filter showed that the powder particles are relatively spherical and considerably porous, which is often seen in spray-freeze drying with vacuum.


Mannitol has been spray-frozen by us at −50° C. to −70° C. and dried in a temperature of −5° C. to −20° C. in order to avoid mannitol crystallization (mannitol hydrate occurs at around 38° C.). Based on practical demand (each bio-substance may have its ideal spray-freeze and drying temperature), the spray-freeze drying conditions are adjustable by changing the temperature and flow rate of the mixed cold gases. Depending on the batch scale, these parameters may be different.


For atmospheric pressure freeze drying with dry air, the temperature at which material may be truly freeze dried is set by its melting point. Since the vapor pressure of ice is essentially fixed by the melting point temperature, the rate of freeze-drying is essentially controlled by the resistance to water vapor diffusion in the material. This resistance is proportional to the diffusion path length and the permeability of the material. Atmospheric pressure freeze-drying should therefore be feasible in a wide variety of materials where diffusion distances are very short in materials of open structure.


Immaterial modifications may be made to the invention described here without departing from the invention.

Claims
  • 1. A method of creating a powder, comprising the steps of: spraying a carrier liquid into a chamber, the carrier liquid containing a powder forming ingredient to form a flow of liquid droplets containing the carrier liquid and powder forming ingredient;entraining the flow of liquid droplets within a flow of coolant for sufficient time to freeze the liquid droplets into frozen particles, the flow of coolant entering the chamber around the flow of liquid droplets and frozen particles to screen the frozen particles from contacting walls of the chamber; anddrying the frozen particles to form a dry powder.
  • 2. The method of claim 1 in which the powder forming ingredient is suspended or dissolved in the carrier liquid prior to spraying the carrier liquid into the chamber.
  • 3. The method of claim 1 in which the flow of coolant is sprayed from a ring nozzle.
  • 4. The method of claim 1 in which the flow of-coolant is injected through porous walls of the chamber.
  • 5. The method of claim 1 in which the frozen particles are collected on a filter.
  • 6. The method of claim 5 in which the frozen particles are substantially dried after being collected on the filter.
  • 7. The method of claim 1 in which the flow of coolant has a temperature within a first temperature range during freezing of the liquid particles and a temperature warmer than the first temperature range during drying of the frozen particles.
  • 8. The method of claim 1 in which the carrier liquid contains more than one powder forming ingredient.
  • 9. The method of claim 1 in which the flow of coolant is co-current with the flow of liquid droplets.
  • 10. The method of claim 1 in which spraying, entraining and freezing of the liquid droplets is carried out within the chamber.
  • 11. The method of claim 10 in which deposition and drying of the frozen particles is carried out within the chamber.
  • 12. The method of claim 1 further comprising depositing the frozen particles on a collector, the liquid droplets being frozen before deposition on the collector, and drying the frozen particles while the frozen particles are collected on the collector.
  • 13. The method of claim 12 in which the collector is a filter at an exit to the chamber.
  • 14. The method of claim 1 in which drying is carried out with a downward flow of coolant.
  • 15. The method of claim 11 in which drying is carried out with a downward flow of coolant.
Priority Claims (1)
Number Date Country Kind
2450779 Dec 2003 CA national
Parent Case Info

This application is a continuation of U.S. patent application Ser. No. 11/318,864 filed Dec. 28, 2005 now U.S. Pat. No. 7,363,726. U.S. patent application Ser. No. 11/318,864 is a continuation of U.S. patent application Ser. No. 10/762,300 filed Jan. 23, 2004, now U.S. Pat. No. 7,007,406.

US Referenced Citations (443)
Number Name Date Kind
2460546 Stephanoff Feb 1949 A
2856278 Bray et al. Oct 1958 A
3172546 Schreiner Mar 1965 A
3247014 Goldberger et al. Apr 1966 A
3252776 Strickland et al. May 1966 A
3257815 Brocoff et al. Jun 1966 A
3309777 Hutton Mar 1967 A
3313032 Malecki Apr 1967 A
3319344 Sachsel et al. May 1967 A
3490355 Groth et al. Jan 1970 A
3565039 Remer Feb 1971 A
3677405 Keith, Jr. Jul 1972 A
3749378 Rhodes Jul 1973 A
3788095 Murphy et al. Jan 1974 A
3793003 Othmer Feb 1974 A
3819336 Rogers et al. Jun 1974 A
3848068 Rice Nov 1974 A
3853541 Othmer Dec 1974 A
3938988 Othmer Feb 1976 A
4015749 Arzberger et al. Apr 1977 A
4033048 Van Ike Jul 1977 A
4094808 Stewart et al. Jun 1978 A
4161084 Arny et al. Jul 1979 A
4273790 Bosco et al. Jun 1981 A
4273795 Bosco et al. Jun 1981 A
4276381 Sakimae et al. Jun 1981 A
4324707 Hungerford Apr 1982 A
4389794 Bitterly Jun 1983 A
4393817 Lindberg Jul 1983 A
4409253 Morrison et al. Oct 1983 A
4409931 Lindberg Oct 1983 A
4455135 Bitterly Jun 1984 A
4533572 Neelameggham et al. Aug 1985 A
4541367 Lindberg Sep 1985 A
4541867 Neelameggham et al. Sep 1985 A
4608764 Leuenberger Sep 1986 A
4652434 Bonsack et al. Mar 1987 A
4768446 Wilkes et al. Sep 1988 A
4775000 Ayers Oct 1988 A
4802286 Kobayashi et al. Feb 1989 A
4820627 McGeehan Apr 1989 A
4836982 Brupbacher et al. Jun 1989 A
4837005 Brode et al. Jun 1989 A
4851722 Zauderer Jul 1989 A
4873293 Brode et al. Oct 1989 A
4915905 Kampe et al. Apr 1990 A
5009994 McGeehan Apr 1991 A
5015534 Kampe et al. May 1991 A
5019311 Koslow May 1991 A
5090132 Kobayashi et al. Feb 1992 A
5124162 Boskovic et al. Jun 1992 A
5147722 Koslow Sep 1992 A
5208998 Oyler, Jr. May 1993 A
5230162 Oyler, Jr. Jul 1993 A
5230915 Shahidi et al. Jul 1993 A
5240656 Scheeres Aug 1993 A
5269077 Bruttini Dec 1993 A
5348566 Sawyer et al. Sep 1994 A
5387489 Fuller et al. Feb 1995 A
5402992 Saxena Apr 1995 A
5426003 Spengler et al. Jun 1995 A
5455057 Symbolik et al. Oct 1995 A
5468427 Stangle et al. Nov 1995 A
5518709 Sutton et al. May 1996 A
5523065 Stangle et al. Jun 1996 A
5531845 Flanigan et al. Jul 1996 A
5536893 Gudmundsson Jul 1996 A
5611973 Gurfein et al. Mar 1997 A
5612053 Baichwal et al. Mar 1997 A
5641349 Koubek et al. Jun 1997 A
5651952 Grudnoff et al. Jul 1997 A
5651966 Read et al. Jul 1997 A
5656498 Iijima et al. Aug 1997 A
5660774 Stangle et al. Aug 1997 A
5665276 Kirby et al. Sep 1997 A
5674468 Klaveness et al. Oct 1997 A
5676925 Klaveness et al. Oct 1997 A
5727333 Folan Mar 1998 A
5731540 Flanigan et al. Mar 1998 A
5738865 Baichwal et al. Apr 1998 A
5772912 Lockyer et al. Jun 1998 A
5780055 Habib et al. Jul 1998 A
5785976 Westesen et al. Jul 1998 A
5795562 Klaveness et al. Aug 1998 A
5829255 Sitnyakovsky et al. Nov 1998 A
5837193 Childers et al. Nov 1998 A
5843347 Nguyen et al. Dec 1998 A
5885486 Westesen et al. Mar 1999 A
5902608 Read et al. May 1999 A
5928469 Franks et al. Jul 1999 A
5957848 Sutton et al. Sep 1999 A
5993804 Read et al. Nov 1999 A
6015546 Sutton et al. Jan 2000 A
6022525 Sutton et al. Feb 2000 A
6050990 Tankovich et al. Apr 2000 A
6074737 Jordan et al. Jun 2000 A
6187226 Detering et al. Feb 2001 B1
6207178 Westesen et al. Mar 2001 B1
6248363 Patel et al. Jun 2001 B1
6251193 Rossy et al. Jun 2001 B1
6251463 Rossy et al. Jun 2001 B1
6261679 Chen et al. Jul 2001 B1
6284282 Maa et al. Sep 2001 B1
6287550 Trinh et al. Sep 2001 B1
6344182 Sutton et al. Feb 2002 B1
6348186 Sutton et al. Feb 2002 B1
6372258 Platz et al. Apr 2002 B1
6387394 Baichwal et al. May 2002 B1
6391224 Wowk May 2002 B1
6395197 Detering et al. May 2002 B1
6413458 Pearce Jul 2002 B1
6416741 Sutton et al. Jul 2002 B1
6426210 Franks et al. Jul 2002 B1
6440336 Weinreich et al. Aug 2002 B1
6440463 Feldstein et al. Aug 2002 B1
6460376 Jeanvoine et al. Oct 2002 B1
6470592 Akimoto et al. Oct 2002 B2
6471993 Shastri et al. Oct 2002 B1
6509006 Platz et al. Jan 2003 B1
6541001 Gallili et al. Apr 2003 B1
6565927 Drzal et al. May 2003 B1
6569405 Sutton et al. May 2003 B1
6569463 Patel et al. May 2003 B2
6572910 Lanner et al. Jun 2003 B2
6582728 Platz et al. Jun 2003 B1
6592869 Gallili et al. Jul 2003 B2
6603054 Chen et al. Aug 2003 B2
6616858 Fahy et al. Sep 2003 B2
6630121 Sievers et al. Oct 2003 B1
6673335 Platz et al. Jan 2004 B1
6695238 Inoki et al. Feb 2004 B2
6716629 Hess et al. Apr 2004 B2
6739152 Jeanvoine et al. May 2004 B2
6749554 Snow et al. Jun 2004 B1
6797258 Platz et al. Sep 2004 B2
6825031 Franks et al. Nov 2004 B2
6830767 Teras et al. Dec 2004 B2
6862890 Williams et al. Mar 2005 B2
6893645 Loughman May 2005 B1
6921527 Platz et al. Jul 2005 B2
6923988 Patel et al. Aug 2005 B2
6931888 Shekunov et al. Aug 2005 B2
6936279 Guerra-Santos et al. Aug 2005 B2
6939530 Sutton et al. Sep 2005 B2
6941676 Akimoto et al. Sep 2005 B2
6973931 King Dec 2005 B1
7007406 Wang et al. Mar 2006 B2
7022313 O'Connor et al. Apr 2006 B2
7028478 Prentice, III Apr 2006 B2
7056877 Caswell et al. Jun 2006 B2
7060213 Pearce Jun 2006 B2
7073349 Shekunov et al. Jul 2006 B2
7076822 Pearce Jul 2006 B2
7089681 Herbert et al. Aug 2006 B2
7091171 Caswell et al. Aug 2006 B2
7094451 Drzal et al. Aug 2006 B2
7097675 Detering et al. Aug 2006 B2
7097827 Platz et al. Aug 2006 B2
7109166 Moreau Sep 2006 B1
7122176 Stamets Oct 2006 B2
7166565 Caswell et al. Jan 2007 B2
7172766 Baichwal et al. Feb 2007 B2
7179484 Singh Feb 2007 B2
7186680 Caswell et al. Mar 2007 B2
7192588 Gallili et al. Mar 2007 B2
7220365 Qu et al. May 2007 B2
7223447 Brown et al. May 2007 B2
7229645 Maa et al. Jun 2007 B2
7247288 Kumta et al. Jul 2007 B2
7278843 Feldstein et al. Oct 2007 B2
7288616 Tamareselvy et al. Oct 2007 B2
7326691 Duddu et al. Feb 2008 B2
7342079 Sher et al. Mar 2008 B2
7351779 Iaccino et al. Apr 2008 B2
7354597 Johnson et al. Apr 2008 B2
7363726 Wang et al. Apr 2008 B2
7369797 Yoshida et al. May 2008 B2
7374779 Chen et al. May 2008 B2
7423103 Stavens et al. Sep 2008 B2
7446084 Barthel et al. Nov 2008 B2
7448379 Yamashita et al. Nov 2008 B2
7465468 Cheney et al. Dec 2008 B1
7494965 Caswell et al. Feb 2009 B2
7497877 Goedhart et al. Mar 2009 B2
7513121 Zurecki et al. Apr 2009 B2
7513132 Wright et al. Apr 2009 B2
7517628 Hirano et al. Apr 2009 B2
7534304 Conrad et al. May 2009 B2
7534758 Caswell et al. May 2009 B2
7544651 Caswell et al. Jun 2009 B2
7553440 Leonard Jun 2009 B2
7578960 Forbes Jones et al. Aug 2009 B2
7624595 Jeanvoine et al. Dec 2009 B2
7628999 Sunkara Dec 2009 B2
7629331 Pipkin et al. Dec 2009 B2
7642533 Partio et al. Jan 2010 B2
7645351 Ohno et al. Jan 2010 B2
7649047 Tamareselvy et al. Jan 2010 B2
7658998 Brown et al. Feb 2010 B2
7682766 Fujimoto et al. Mar 2010 B2
7731954 Davis et al. Jun 2010 B2
7735485 Yamashita et al. Jun 2010 B2
7758327 Leonard Jul 2010 B2
7767249 Chinea et al. Aug 2010 B2
7836606 Gehrmann et al. Nov 2010 B2
20010024716 Chen et al. Sep 2001 A1
20010041743 Offenbacher et al. Nov 2001 A1
20020018837 Lanner et al. Feb 2002 A1
20020018838 Zimmerman et al. Feb 2002 A1
20020022076 Lanner et al. Feb 2002 A1
20020028273 Teras et al. Mar 2002 A1
20020034571 Zimmerman et al. Mar 2002 A1
20020050072 Akimoto et al. May 2002 A1
20020061336 O'Connor et al. May 2002 A1
20020063235 Fahy et al. May 2002 A1
20020072509 Stein et al. Jun 2002 A1
20020090345 Baichwal et al. Jul 2002 A1
20020094533 Hess et al. Jul 2002 A1
20020117170 Platz et al. Aug 2002 A1
20020120228 Maa et al. Aug 2002 A1
20020127188 Platz et al. Sep 2002 A1
20020146394 Stamets Oct 2002 A1
20020151604 Detering et al. Oct 2002 A1
20020187182 Kramer et al. Dec 2002 A1
20020189127 Akimoto et al. Dec 2002 A1
20020193290 Feldstein et al. Dec 2002 A1
20030006326 Inoki et al. Jan 2003 A1
20030026813 Gallili et al. Feb 2003 A1
20030029197 Jeanvoine et al. Feb 2003 A1
20030040462 Franks et al. Feb 2003 A1
20030059435 Gallili et al. Mar 2003 A1
20030064097 Patel et al. Apr 2003 A1
20030066638 Qu et al. Apr 2003 A1
20030068279 Platz et al. Apr 2003 A1
20030077297 Chen et al. Apr 2003 A1
20030086877 Platz et al. May 2003 A1
20030096899 Pearce May 2003 A1
20030098438 Haslin May 2003 A1
20030101995 Yamashita et al. Jun 2003 A1
20030104969 Caswell et al. Jun 2003 A1
20030116748 Haslim Jun 2003 A1
20030124716 Hess et al. Jul 2003 A1
20030129141 Platz et al. Jul 2003 A1
20030133876 Sutton et al. Jul 2003 A1
20030180352 Patel et al. Sep 2003 A1
20030180755 Hwang et al. Sep 2003 A1
20030180807 Hess et al. Sep 2003 A1
20030185765 Platz et al. Oct 2003 A1
20030186271 Hwang et al. Oct 2003 A1
20030194506 Drzal et al. Oct 2003 A1
20030198601 Platz et al. Oct 2003 A1
20030202978 Maa et al. Oct 2003 A1
20030207988 Tamareselvy et al. Nov 2003 A1
20030215496 Patel et al. Nov 2003 A1
20030219466 Kumta et al. Nov 2003 A1
20030220039 Chen et al. Nov 2003 A1
20030232020 York et al. Dec 2003 A1
20030232892 Guerra-Santos et al. Dec 2003 A1
20040036054 Haslim Feb 2004 A1
20040043042 Johnson et al. Mar 2004 A1
20040099612 Herbert et al. May 2004 A1
20040117919 Conrad et al. Jun 2004 A1
20040139555 Conrad et al. Jul 2004 A1
20040154317 Shekunov et al. Aug 2004 A1
20040162333 Mezaache et al. Aug 2004 A1
20040173146 Figueroa et al. Sep 2004 A1
20040173147 Figueroa et al. Sep 2004 A1
20040175331 Figueroa et al. Sep 2004 A1
20040206124 Jeanvoine et al. Oct 2004 A1
20040226098 Pearce Nov 2004 A1
20040226099 Pearce Nov 2004 A1
20040226726 Holland et al. Nov 2004 A1
20040229986 Pearce Nov 2004 A1
20040241800 Jue et al. Dec 2004 A1
20040247660 Singh Dec 2004 A1
20040247870 Brown et al. Dec 2004 A1
20050017396 Pearce et al. Jan 2005 A1
20050026793 Caswell et al. Feb 2005 A1
20050089548 Virgalitto et al. Apr 2005 A1
20050089576 Moreau Apr 2005 A1
20050091755 Conrad et al. May 2005 A1
20050091756 Wright et al. May 2005 A1
20050092352 Luckman et al. May 2005 A1
20050106553 Franks et al. May 2005 A1
20050118939 Duescher Jun 2005 A1
20050119165 Jue et al. Jun 2005 A1
20050126606 Goedhart et al. Jun 2005 A1
20050150059 Luckman et al. Jul 2005 A1
20050152946 Hunter et al. Jul 2005 A1
20050154374 Hunter et al. Jul 2005 A1
20050155393 Wright et al. Jul 2005 A1
20050158356 Hunter et al. Jul 2005 A1
20050160615 Wang et al. Jul 2005 A1
20050161845 Haas Jul 2005 A1
20050169960 Hunter et al. Aug 2005 A1
20050169961 Hunter et al. Aug 2005 A1
20050175664 Hunter et al. Aug 2005 A1
20050175665 Hunter et al. Aug 2005 A1
20050175703 Hunter et al. Aug 2005 A1
20050176611 Caswell et al. Aug 2005 A1
20050178020 Shekunov et al. Aug 2005 A1
20050178395 Hunter et al. Aug 2005 A1
20050178396 Hunter et al. Aug 2005 A1
20050181005 Hunter et al. Aug 2005 A1
20050181009 Hunter et al. Aug 2005 A1
20050181010 Hunter et al. Aug 2005 A1
20050182463 Hunter et al. Aug 2005 A1
20050183731 Hunter et al. Aug 2005 A1
20050186239 Hunter et al. Aug 2005 A1
20050186244 Hunter et al. Aug 2005 A1
20050186245 Hunter et al. Aug 2005 A1
20050187140 Hunter et al. Aug 2005 A1
20050187188 Stein et al. Aug 2005 A1
20050189049 Ohno et al. Sep 2005 A1
20050191361 O'Connor et al. Sep 2005 A1
20050196421 Hunter et al. Sep 2005 A1
20050202990 Caswell et al. Sep 2005 A1
20050208095 Hunter et al. Sep 2005 A1
20050211029 Zurecki et al. Sep 2005 A1
20050214227 Prestrelski et al. Sep 2005 A1
20050238586 Sutton et al. Oct 2005 A1
20050260273 Chinea et al. Nov 2005 A1
20050260274 Chinea et al. Nov 2005 A1
20050266021 Maa et al. Dec 2005 A1
20050271737 Chinea et al. Dec 2005 A1
20060025355 Duddu et al. Feb 2006 A1
20060034816 Davis et al. Feb 2006 A1
20060034903 Maa et al. Feb 2006 A1
20060034937 Patel Feb 2006 A1
20060035027 Brown et al. Feb 2006 A1
20060053791 Prentice Mar 2006 A1
20060057106 Yamashita et al. Mar 2006 A1
20060057213 Larhrib et al. Mar 2006 A1
20060073105 Yamashita et al. Apr 2006 A1
20060123556 Caswell et al. Jun 2006 A1
20060123557 Caswell et al. Jun 2006 A1
20060130355 Wang et al. Jun 2006 A1
20060135921 Wiercinski et al. Jun 2006 A1
20060144869 Chang et al. Jul 2006 A1
20060147389 Staniforth et al. Jul 2006 A1
20060157507 Chang et al. Jul 2006 A1
20060159821 Brisson et al. Jul 2006 A1
20060191375 Feldstein et al. Aug 2006 A1
20060204282 Yoshida et al. Sep 2006 A1
20060210622 Pace et al. Sep 2006 A1
20060225422 Prentice Oct 2006 A1
20060253988 Pearce Nov 2006 A1
20060254419 Leonard Nov 2006 A1
20060269861 Hirano et al. Nov 2006 A1
20060286205 Fichtali et al. Dec 2006 A1
20070003492 Kitahata et al. Jan 2007 A1
20070019148 Ueda Jan 2007 A1
20070042048 Platz et al. Feb 2007 A1
20070043030 Morton et al. Feb 2007 A1
20070057416 Kennedy Mar 2007 A1
20070062332 Jones et al. Mar 2007 A1
20070065371 Yamashita et al. Mar 2007 A2
20070093440 Champion et al. Apr 2007 A1
20070111918 Caswell et al. May 2007 A1
20070114298 O'Keefe May 2007 A1
20070117939 Iaccino et al. May 2007 A1
20070122418 Platz et al. May 2007 A1
20070123477 Malcolmson et al. May 2007 A1
20070129297 Cochrane Jun 2007 A1
20070166368 Singh Jul 2007 A1
20070167340 Barthel et al. Jul 2007 A1
20070178399 Kobayashi et al. Aug 2007 A1
20070190158 Hwang et al. Aug 2007 A1
20070197957 Hunter et al. Aug 2007 A1
20070202342 Whiteford et al. Aug 2007 A1
20070203047 Pegelow et al. Aug 2007 A1
20070203209 Bartolini et al. Aug 2007 A1
20070208154 Stavens et al. Sep 2007 A1
20070219325 Sher et al. Sep 2007 A1
20070224128 Dennis et al. Sep 2007 A1
20070241306 Wehner et al. Oct 2007 A1
20070254233 Fujimoto et al. Nov 2007 A1
20070269392 Sunkara Nov 2007 A1
20080009432 Caswell et al. Jan 2008 A1
20080020127 Whiteford et al. Jan 2008 A1
20080021212 Whiteford et al. Jan 2008 A1
20080023657 Melnychuk et al. Jan 2008 A1
20080026068 Brown et al. Jan 2008 A1
20080038356 Maa et al. Feb 2008 A1
20080045646 Tamareselvy et al. Feb 2008 A1
20080050793 Durance et al. Feb 2008 A1
20080060213 Gehrmann et al. Mar 2008 A1
20080075777 Kennedy Mar 2008 A1
20080091233 Ellis-Behnke et al. Apr 2008 A1
20080095820 Kumta et al. Apr 2008 A1
20080142166 Carson et al. Jun 2008 A1
20080145658 Richard et al. Jun 2008 A1
20080155853 Wang et al. Jul 2008 A1
20080161233 Moreau Jul 2008 A1
20080172047 Altshuler et al. Jul 2008 A1
20080179034 Forbes Jones et al. Jul 2008 A1
20080183162 Altshuler et al. Jul 2008 A1
20080194494 Martinez et al. Aug 2008 A1
20080207581 Whiteford et al. Aug 2008 A1
20080214988 Altshuler et al. Sep 2008 A1
20080223758 Scheeres Sep 2008 A1
20080241269 Velasquez Oct 2008 A1
20080305271 Ring et al. Dec 2008 A1
20080306471 Altshuler et al. Dec 2008 A1
20090000758 Stone et al. Jan 2009 A1
20090011037 Pipkin et al. Jan 2009 A1
20090016964 Kalechofsky et al. Jan 2009 A1
20090053318 Tan et al. Feb 2009 A1
20090059138 Matsumoto et al. Mar 2009 A1
20090062173 Caswell et al. Mar 2009 A1
20090069741 Altshuler et al. Mar 2009 A1
20090074859 Patel Mar 2009 A1
20090095293 Yamashita et al. Apr 2009 A1
20090118503 Sprott et al. May 2009 A1
20090123540 Pipkin et al. May 2009 A1
20090126732 Yamashita et al. May 2009 A1
20090131395 Antonelli et al. May 2009 A1
20090136737 Ring et al. May 2009 A1
20090169500 Sunkara Jul 2009 A1
20090190073 Yoshino et al. Jul 2009 A1
20090238878 Singh Sep 2009 A1
20090263555 Tapfer et al. Oct 2009 A1
20090264653 Bartolini et al. Oct 2009 A1
20090272228 Forbes Jones et al. Nov 2009 A1
20090272269 Leonard Nov 2009 A1
20090280534 Christensen et al. Nov 2009 A1
20090311406 Tapfer et al. Dec 2009 A1
20090312724 Pipkin et al. Dec 2009 A1
20090323459 Windhab et al. Dec 2009 A1
20100035789 Caswell et al. Feb 2010 A1
20100055049 Kuo et al. Mar 2010 A1
20100055266 Windhab et al. Mar 2010 A1
20100076108 Miyashita et al. Mar 2010 A1
20100115708 Caswell et al. May 2010 A1
20100168011 Jennings et al. Jul 2010 A1
20100173005 Prestrelski et al. Jul 2010 A1
20100190722 Bevec et al. Jul 2010 A1
20100197708 Talley et al. Aug 2010 A1
20100247712 Rudolph Sep 2010 A1
20100258118 Morton Oct 2010 A1
20100263696 Leonard Oct 2010 A1
20100326437 Zeng Dec 2010 A1
20110020947 Bedingham et al. Jan 2011 A1
Foreign Referenced Citations (29)
Number Date Country
2004269422 Mar 2005 AU
2375250 Dec 2000 CA
2386206 Apr 2001 CA
4200678 Jul 1992 DE
4113512 Oct 1992 DE
19750679 May 1999 DE
546597 Jun 1993 EP
S53-114783 Oct 1978 JP
55015788 Feb 1980 JP
55102369 Aug 1980 JP
58138347 Aug 1983 JP
60096530 May 1985 JP
63017670 Jan 1988 JP
S63-36817 Jul 1988 JP
03004946 Jan 1991 JP
06062744 Mar 1994 JP
06292705 Oct 1994 JP
H07-080271 Mar 1995 JP
08280807 Oct 1996 JP
11178509 Jul 1999 JP
2001-518391 Oct 2001 JP
2002-058981 Feb 2002 JP
2002338965 Nov 2002 JP
7900086 Feb 1979 WO
WO 8810150 Dec 1988 WO
WO 03043574 May 2003 WO
03072016 Sep 2003 WO
2005021807 Mar 2005 WO
WO 2005061088 Jul 2005 WO
Related Publications (1)
Number Date Country
20080155853 A1 Jul 2008 US
Continuations (2)
Number Date Country
Parent 11318864 Dec 2005 US
Child 12050654 US
Parent 10762300 Jan 2004 US
Child 11318864 US